Clinical trials: Aplastic Anaemia
Septic Shock, Nonchemotherapy Drug-induced Neutropenia
Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia
Septic shock remains a significant clinical problem associated with high rates of mortality among neutropenic patient despite antimicrobial therapy and supportive care.
- Conditions
- Septic Shock, Nonchemotherapy Drug-induced Neutropenia, Neutropenia After Chemotherapy in Oncohematological Patients, Neutropenia in Patients With Aplastic Anemia
- Trial name
- NCT01849237
- Testing
- Mesenchymal stromal cells, Standard therapy of septic shock
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- National Research Center for Hematology, Russia
Severe Aplastic Anemia
Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia
Severe acquired aplastic anaemia (SAA) is a life-threatening disease characterized by pancytopenia and hypoplastic bone marrow. Immunosuppressive treatment with antithymocyte globulin (ATG)and cyclosporine remain the standard…
- Trial name
- NCT01997372
- Testing
- ATG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese Academy of Medical Sciences
Aplastic Anemia
CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with severe aplastic anemia
- Trial name
- NCT06633328
- Testing
- CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Anemia, Aplastic, Anemia, Hypoplastic
A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients
Severe aplastic anemia (SAA) is a life-threatening blood disease which can be effectively treated with immunosuppressive drug regimens or allogeneic stem cell transplantation.
- Conditions
- Anemia, Aplastic, Anemia, Hypoplastic, Thrombocytopenia
- Trial name
- NCT00922883
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pure Red Cell Aplasia
Tacrolimus Treatment for Refractory PRCA
Pure red cell aplasia (PRCA) is a kind of anemia characterized by severe reticulocytopenia and obvious bone marrow erythroblastic cells decreased.
- Trial name
- NCT03540472
- Testing
- tacrolimus
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Severe Aplastic Anemia
Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia
The aim of this study was to evaluate the safety and efficacy of a modified allogeneic hematopoietic stem cell transplantation regimen for aplastic anemia.
- Trial name
- NCT06378060
- Testing
- Modified transplantation system
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hematology department of the 920th hospital
Anemia, Breast Neoplasms
A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer
The purpose of this study is to determine whether it is possible to measure temporary difficulty with thinking and/or short-term memory in women who are receiving chemotherapy for early stage breast cancer and to determine…
- Conditions
- Anemia, Breast Neoplasms, Hemoglobins, Quality of Life
- Trial name
- NCT00246597
- Testing
- epoetin alfa
- Volunteers
- 37 people
- Sponsor
- Ortho Biotech Products, L.P.
Aplastic Anemia
Stem Cell Mobilization Potential in Patients With Aplastic Anemia in Remission
This study will examine 1) whether it is possible to collect enough stem cells (cells produced by the bone marrow that mature into white and red blood cells and platelets) from patients with aplastic anemia to use for future…
- Trial name
- NCT00011830
- Testing
- G-CSF, Apheresis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00301834
- Testing
- alemtuzumab, busulfan, cyclosporine
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Francisco
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
This phase II trial studies how well fludarabine phosphate, cyclophosphamide, total body irradiation, and donor stem cell transplant work in treating patients with blood cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT03333486
- Testing
- Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Roswell Park Cancer Institute
Severe Aplastic Anemia
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated.
- Trial name
- BMT CTN CureAA (NCT06517641)
- Testing
- Haploidentical donor bone marrow transplant, Unrelated donor bone marrow transplant
- Where
- 25 sites in United States
- Volunteers
- 60 people
- Sponsor
- Medical College of Wisconsin
Aplastic Anemia
Alefacept in Patients With Relapsed/Refractory Aplastic Anemia
Aplastic Anemia (AA) is an autoimmune hematologic stem cell disease mediated by activated T-lymphocytes that leads to pancytopenia. The disease related morbidity and mortality if left untreated can approach 90%.
- Trial name
- NCT01267643
- Testing
- Alefacept
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Aplastic Anemia
Study of Fludarabine + Cyclophosphamide + TBI Conditioning Regimen for Double Units Cord Blood Transplantation(CBT)in Severe Aplastic Anemia(SAA)
Severe aplastic anemia is a fatal disease and patients without HLA matched siblings need alternative treatment option. Cord blood transplantation (CBT) has become an alternative treatment means in various diseases, but it has not…
- Trial name
- NCT00881933
- Testing
- Cyclophosphosphamide, TBI
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- The Korean Society of Pediatric Hematology Oncology
Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS)
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
Background: Severe aplastic anemia (SAA), and myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH) cause serious blood problems.
- Conditions
- Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Trial name
- NCT03520647
- Testing
- Cyclophosphamide, Peripheral Blood Stem Cells
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Aplastic Anemia
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Aplastic Anemia
This study is to evaluate the safety and efficacy of Umbilical Cord Derived Mesenchymal Stem Cells transplantation in aplastic anemia.
- Trial name
- NCT03055078
- Testing
- mesenchymal stem cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hebei Medical University
Aplastic Anemia, Stem Cell Transplant Complications
Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA
The haplotype HSCT system including Bu(0.8mg/kg Q6hx2d)CTX(50mg/kgx4d)rATG(2.5mg/kgx4d) , established in Institute of Hematology of Peking University ,has been evaluated to be effective for acquired SAA.But some patients with…
- Conditions
- Aplastic Anemia, Stem Cell Transplant Complications, Engraft Failure
- Trial name
- NCT03821987
- Testing
- Fludarabine
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Peking University People's Hospital
Acute Myeloid Leukemia, Myelodysplasia
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia
The primary objective of this study is to examine transplant related mortality (TRM) at 100 days <30%. A TRM of >50% is considered unacceptable.
- Conditions
- Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00513175
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Fanconi Anemia
A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia
This is a multi-center, Phase 1/2 study to determine the Optimal Biologic Dose (OBD) and to evaluate the safety, tolerability, PK, and preliminary activity of FP 045 when administered orally in young adult/adolescent and…
- Trial name
- NCT04522375
- Testing
- FP-045
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
PNH, Thrombosis
Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones
The present study is a non-interventional retrospective chart review study assessing the prevalence of PNH-clones in patients with PNH risk-factors aged ≥14 years and treated at our hospital.
- Trial name
- NCT05884060
- Testing
- No intervention
- Where
- Belgium
- Volunteers
- 568 people
- Sponsor
- AZ Delta
Diamond Blackfan Anemia, Pure Red Cell Aplasia
The Use of Trifluoperazine in Transfusion Dependent DBA
Diamond Blackfan anemia (DBA) is a rare inherited pure red cell aplasia. The two main non-stem cell transplant therapeutic options are corticosteroids and red blood cell (RBC) transfusions.
- Trial name
- DBA (NCT03966053)
- Testing
- Trifluoperazine
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Adrianna Vlachos, MD